Drugs / VVN432
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07259538 | Nov 2025 → Jul 2026 overdue | chronic rhinosinusitis | VivaVision Biotech, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVN432 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07259538 ↗ |
| Route | Intranasal | “VVN432 Nasal Spray” NCT07259538 ↗ |